ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
FTSE 100
8,272.98
0.87%
Dow Jones
43,180.53
1.56%
Gold vs US Dollar
2,689.225
0.78%
Brent Oil
80.125
0.53%
Bitcoin
98,896.57
2.48%
Pepperstone
Advertisement
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. BridgeBio Pharma Inc (BBIO)

  7. BridgeBio Pharma Inc (BBIO) News

BridgeBio Pharma (BBIO)

BridgeBio Pharma Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:BBIO
DateTimeSourceHeadlineSymbolCompany
13/01/202521:53Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BBIOBridgeBio Pharma Inc
13/01/202516:00GlobeNewswire Inc.BridgeBio Announces Commercial Progress, Program Updates, and 2025 MilestonesNASDAQ:BBIOBridgeBio Pharma Inc
08/01/202512:30GlobeNewswire Inc.BridgeBio Pharma to Participate in the J.P. Morgan Healthcare ConferenceNASDAQ:BBIOBridgeBio Pharma Inc
13/12/202412:18GlobeNewswire Inc.Acoramidis Receives Positive CHMP Opinion for Treatment of Transthyretin Amyloid Cardiomyopathy (ATTR-CM)NASDAQ:BBIOBridgeBio Pharma Inc
13/12/202400:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BBIOBridgeBio Pharma Inc
13/12/202400:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BBIOBridgeBio Pharma Inc
23/11/202402:16Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BBIOBridgeBio Pharma Inc
23/11/202400:11GlobeNewswire Inc.Attruby™ (acoramidis), a Near Complete TTR Stabilizer (≥90%), approved by FDA to Reduce Cardiovascular Death and Cardiovascular-related Hospitalization in ATTR-CM PatientsNASDAQ:BBIOBridgeBio Pharma Inc
21/11/202400:57Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BBIOBridgeBio Pharma Inc
19/11/202423:13Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BBIOBridgeBio Pharma Inc
19/11/202423:06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BBIOBridgeBio Pharma Inc
19/11/202421:28Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:BBIOBridgeBio Pharma Inc
18/11/202416:15GlobeNewswire Inc.Open-Label Extension Data Confirms Sustained Benefit of Acoramidis on Cardiovascular Outcomes, Including Statistically Significant Reduction in ACM Within 36 MonthsNASDAQ:BBIOBridgeBio Pharma Inc
18/11/202410:30GlobeNewswire Inc.BridgeBio Pharma Announces Publication in the New England Journal of Medicine of Phase 2 PROPEL 2 Study of Infigratinib for Children Living with AchondroplasiaNASDAQ:BBIOBridgeBio Pharma Inc
12/11/202412:30GlobeNewswire Inc.BridgeBio Pharma Reports Third Quarter 2024 Financial Results and Business UpdateNASDAQ:BBIOBridgeBio Pharma Inc
05/11/202412:30GlobeNewswire Inc.BridgeBio Announces Publication of Case Study Exploring Portfolio Theory’s Impact on Biomedical Innovation in The Journal of Portfolio ManagementNASDAQ:BBIOBridgeBio Pharma Inc
24/10/202411:30GlobeNewswire Inc.BridgeBio Shares Positive Data from High Dose Cohort of Phase 1/2 CANaspire Study of Gene Therapy BBP-812 for Canavan Disease at ESGCT 2024NASDAQ:BBIOBridgeBio Pharma Inc
22/10/202422:06Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:BBIOBridgeBio Pharma Inc
03/10/202411:30GlobeNewswire Inc.BridgeBio to Present Outcomes Data Through 42 Months from the Open-Label Extension of ATTRibute-CM, the Phase 3 Study of Acoramidis for Treatment of ATTR-CM, at 2024 AHA Scientific SessionsNASDAQ:BBIOBridgeBio Pharma Inc
30/09/202411:30GlobeNewswire Inc.BridgeBio Completes Enrollment of FORTIFY, Phase 3 Registrational Study of BBP-418 in Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)NASDAQ:BBIOBridgeBio Pharma Inc
27/09/202422:00GlobeNewswire Inc.BridgeBio Shares Recurrent Event Analysis of ATTRibute-CM, Demonstrating a 42% Reduction by Acoramidis on the Composite Endpoint of All-Cause Mortality and Recurrent Cardiovascular-related Hospitalization EventsNASDAQ:BBIOBridgeBio Pharma Inc
17/09/202422:41Edgar (US Regulatory)Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]NASDAQ:BBIOBridgeBio Pharma Inc
17/09/202411:30GlobeNewswire Inc.BridgeBio Announces Infigratinib Is the First Ever Investigational Therapeutic Option for Achondroplasia to Be Awarded Breakthrough Therapy Designation by the FDANASDAQ:BBIOBridgeBio Pharma Inc
13/09/202421:04Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:BBIOBridgeBio Pharma Inc
10/09/202420:45GlobeNewswire Inc.BridgeBio Pharma Reports Topline Results from Phase 1/2 Trial of Investigational Gene Therapy for Congenital Adrenal Hyperplasia (CAH)NASDAQ:BBIOBridgeBio Pharma Inc
10/09/202420:45GlobeNewswire Inc.BridgeBio Receives FDA’s Regenerative Medicine Advanced Therapy (RMAT) Designation for BBP-812 Canavan Disease Gene Therapy ProgramNASDAQ:BBIOBridgeBio Pharma Inc
06/09/202411:30GlobeNewswire Inc.BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)NASDAQ:BBIOBridgeBio Pharma Inc
30/08/202414:50GlobeNewswire Inc.BridgeBio Shares Data on Serum TTR Increase When Switching Participants from Placebo and Tafamidis to Acoramidis in ATTRibute-CM and its Open-Label ExtensionNASDAQ:BBIOBridgeBio Pharma Inc
29/08/202411:30GlobeNewswire Inc.BridgeBio to Present Additional Analyses from the Phase 3 ATTRibute-CM Trial of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the ESC Congress 2024 and the HFSA Annual Meeting 2024NASDAQ:BBIOBridgeBio Pharma Inc
28/08/202411:30GlobeNewswire Inc.BridgeBio Pharma to Participate in September Investor EventsNASDAQ:BBIOBridgeBio Pharma Inc
 Showing the most relevant articles for your search:NASDAQ:BBIO

Your Recent History

LSE
SYME
Supply@me Capital
LSE
GEX
Georgina Energy
LSE
POS
Plexus
LSE
SCLP
Scancell
LSE
TERN
Tern
LSE
BANK
Fiinu
LSE
QBT
Quantum Blockchain Techn...
LSE
FIN
Finseta
LSE
AAZ
Anglo Asian Mining
LSE
MFAI
Mindflair
LSE
RRR
Red Rock Resources
LSE
LLOY
Lloyds Banking
LSE
BARC
Barclays
LSE
MIN
Minoan
LSE
UPS
LSE
SBTX
Skinbiotherapeutics
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2025 ADVFN PLC - All Rights Reserved

    Go Ad-Free

    Subscribe to Ad free and enjoy an ad-free experience

    No Ads

    Try Now

    Keep the Ads